MarketInOut Stock Screener Log In | Sign Up

Eloxx Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Eloxx Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization53.85 mln
Float2.56 mln
Earnings Date11/11/2026

EPS

3.52
Solid

P / E

3.82
Deeply undervalued

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

38.25
Transformational upside

Relative Strength

80 / 100
Strongly outperforming

Debt / Equity

0.25
Very low leverage

Business Description

Eloxx Pharmaceuticals is a clinical-stage drug development company headquartered in Arlington, Massachusetts, with operations in Israel and Australia. The company focuses on treatments for rare genetic diseases caused by nonsense mutations ? errors in genetic code that cause the body to stop producing essential proteins too early. Its lead drug candidate, ezutromid, is being tested in clinical trials for rare kidney conditions, while a separate compound is being developed with partner Almirall S.A. to treat serious inherited skin disorders.

Key Fundamentals

EPS3.52
P/E3.82
ROE-42.52
ROIC-66.19
ROA-22.97
Interest Cover-223
EBITDA, mln-8.22
EV / EBITDA0.02
EV / EBIT0.02

Quote Details

Last 13.45
Change 0.25 (1.89%)
Open 12.98
Volume 13,988
Turnover 188,139
Average Volume 25,013

Financial Ratios

Leverage Ratio1.37
Current Ratio3.74
Price / Book1.33
Price / Tangible Book1.33
Debt / Equity0.25
PEG Ratio1.85

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price38.25
Short Ratio1.90
Short % of Float1.48

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 5.08% 88 / 100   
1 Month -14.39% 24 / 100   
2 Months 11.07% 88 / 100   
6 Months 715% 100 / 100   
1 Year 1222627% 100 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog